Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.

Trial Details

NCT ID
NCT07422610
Phase
PHASE1
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • pelabresib
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Saint-Herblain, France|47.21154,-1.651
  • Milan, MI, Italy|42.78235,12.59836
  • Milan, MI, Italy|42.78235,12.59836
  • Candiolo, TO, Italy|44.95858,7.59812

Key Eligibility Criteria

  • Is at least 18 and not older than 75 years of age at the time of signing the informed consent.
  • Group 1 only: There is a matching participant in Group 2 and an enrollment slot is available for the Group 1 participant.
  • Has a confirmed documented diagnosis of an advanced malignancy for which no standard and/or curative treatment options are available.
  • Has the following acceptable laboratory assessments prior to the first dose of study treatment:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →